Travere Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Travere Therapeutics, Inc. (TVTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TVTX insiders buying or selling?
In the last 12 months, Travere Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 61 sales ($104.2M) — net selling of $104.2M. Since January 2018, Trabud has recorded 269 Form 4 filings for TVTX: 0 buys ($0) and 269 sells ($128.6M).
Source: SEC EDGAR Form 4
What stands out
- No Travere Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 61 reported open-market sales totaled $104.2M.
Key Statistics (January 2018 – Sep 18, 2026)
Total Form 4 filings
269
SEC EDGAR
Insider filers
15
Insider buys (0)
$0
Insider sells (269)
$128.6M
Insider sentiment
Net sellingNet insider flow of $128.6M in net selling since January 2018, and $104.2M in net selling over the last 12 months.
Recent TVTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | William E. Rote | Chief Research Officer | Sale | 209.0K | $62.83 | $13.1M | SEC ↗ |
| Sep 18, 2026 | Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sale | 283.2K | $63.06 | $17.9M | SEC ↗ |
| Sep 18, 2026 | Jula Inrig | EVP, Head of R&D & CMO | Sale | 44.7K | $62.34 | $2.8M | SEC ↗ |
| Sep 18, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 37.5K | $62.34 | $2.3M | SEC ↗ |
| Sep 18, 2026 | Eric M Dube | CHIEF EXECUTIVE OFFICER | Sale | 400.0K | $63.48 | $25.4M | SEC ↗ |
| Sep 18, 2026 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sale | 50.5K | $62.34 | $3.1M | SEC ↗ |
| Sep 18, 2026 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale | 5.4K | $62.33 | $335.0K | SEC ↗ |
| Sep 11, 2026 | Jeffrey A Meckler | Director | Sale | 20.0K | $67.31 | $1.3M | SEC ↗ |
| Sep 3, 2026 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sale | 642 | $66.37 | $42.6K | SEC ↗ |
| Aug 19, 2026 | LYONS GARY A | Director | Sale | 10.0K | $63.28 | $632.8K | SEC ↗ |
| Jun 16, 2026 | Timothy Coughlin | Director | Sale | 10.0K | $50.07 | $500.7K | SEC ↗ |
| Jun 16, 2026 | Roy D. Baynes | Director | Sale | 4.5K | $50.00 | $225.0K | SEC ↗ |
| May 19, 2026 | Timothy Coughlin | Director | Sale | 3.3K | $43.49 | $141.3K | SEC ↗ |
| May 7, 2026 | Roy D. Baynes | Director | Sale | 4.5K | $46.65 | $209.9K | SEC ↗ |
| May 7, 2026 | Jeffrey A Meckler | Director | Sale | 8.0K | $45.00 | $360.0K | SEC ↗ |
| May 7, 2026 | William E. Rote | Chief Research Officer | Sale | 2.8K | $43.95 | $121.4K | SEC ↗ |
| May 7, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 24.3K | $45.06 | $1.1M | SEC ↗ |
| May 7, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale | 22.5K | $45.15 | $1.0M | SEC ↗ |
| May 7, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale | 2.2K | $46.65 | $101.4K | SEC ↗ |
| May 7, 2026 | Eric M Dube | CHIEF EXECUTIVE OFFICER | Sale | 22.5K | $43.95 | $988.9K | SEC ↗ |
| May 7, 2026 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sale | 2.5K | $46.31 | $115.4K | SEC ↗ |
| May 4, 2026 | Roy D. Baynes | Director | Sale | 9.8K | $44.22 | $431.1K | SEC ↗ |
| Apr 23, 2026 | William E. Rote | Chief Research Officer | Sale | 9.1K | $39.09 | $355.7K | SEC ↗ |
| Apr 16, 2026 | LYONS GARY A | Director | Sale | 8.0K | $41.07 | $328.6K | SEC ↗ |
| Apr 16, 2026 | Roy D. Baynes | Director | Sale | 32.8K | $41.29 | $1.4M | SEC ↗ |
Showing the 25 most recent of 269 Form 4 filings for Travere Therapeutics, Inc..
Most active TVTX insiders
- Elizabeth E Reed42 filings
- William E. Rote37 filings
- Eric M Dube31 filings
- Peter Heerma25 filings
- Steve Aselage25 filings
Ask anything about TVTX insider activity
Use Trabud's AI agent to query Travere Therapeutics, Inc.'s Form 4 history in plain English — "Show me TVTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentTVTX insider trading FAQ
Are Travere Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Travere Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 61 sales ($104.2M) — net selling of $104.2M. Since January 2018, Trabud has recorded 269 Form 4 filings for TVTX: 0 buys ($0) and 269 sells ($128.6M). Over the full record that is net selling of $128.6M.
How many insiders trade TVTX stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Travere Therapeutics, Inc.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get TVTX insider trading data?
All TVTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.